ioGlutamatergic Neurons HTT 50CAG/WT - Human iPSC derived cells

Wild type ioGlutamatergic Neurons (ab303447) form the genetically matched control for the ioGlutamatergic Neurons HTT^50CAG/WT disease model. This physiologically-relevant isogenic pairing offers a powerful next generation model to study Huntington's disease in research and drug discovery.

ioGlutamatergic Neurons HTT^50CAG/WT are ioGlutamatergic Neurons carrying the disease-relevant 50 CAG trinucleotide repeat expansion, associated with Huntington's disease. ioGlutamatergic Neuron HTT^50CAG/WT have been reprogrammed from human iPSCs using opti-ox technology, a precise reprogramming technology. Using CRISPR/Cas9 genome editing an abnormal expansion of 50 CAG repeats has been introduced in the first exon of the Huntingtin gene. Human stem cells, within days, convert consistently into mature, functional glutamatergic neurons providing a high quality human model for the study of Huntington's disease.

ioGlutamatergic Neurons HTT^50CAG/WT express pan-neuronal and glutamatergic markers TUBB3, MAP2 and VGLUT2 by day 11, as well as the disease-relevant Huntingtin protein.

This disease model offers a fast and easy-to-use system for investigations into the impact of gene function on disease progression against an isogenic control.

In partnership with bit.bio

Karyotype: Normal

Seeding Density: 30,000 cells/cm²

Seeding compatibility: 6-, 12-, 24-, 96- and 384-well compatible

Quality control: ICC and gene expression analysis

Research applications: Academic research, Drug development, Neurotoxicology, Genetic screening (e.g. CRISPR screening).

This product is subject to limited use licenses from iPS Academia Japan Inc, TET Systems GmbH, ERS Genomics Limited and Sigma-Aldrich Co. LLC and is developed with Bit Bio patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.